Ajanta Pharma Limited Stock

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:46 2024-04-26 EDT 5-day change 1st Jan Change
2,194 INR +2.50% Intraday chart for Ajanta Pharma Limited +5.18% +5.27%

Financials

Sales 2024 * 42.01B 504M 689M Sales 2025 * 47.09B 565M 772M Capitalization 276B 3.31B 4.53B
Net income 2024 * 8.08B 96.91M 132M Net income 2025 * 9.5B 114M 156M EV / Sales 2024 * 6.39 x
Net cash position 2024 * 7.97B 95.6M 131M Net cash position 2025 * 13.8B 166M 226M EV / Sales 2025 * 5.57 x
P/E ratio 2024 *
34.6 x
P/E ratio 2025 *
29.2 x
Employees 7,713
Yield 2024 *
0.92%
Yield 2025 *
0.76%
Free-Float 50.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.50%
1 week+5.18%
Current month-1.67%
1 month-1.33%
3 months+0.39%
6 months+28.45%
Current year+5.27%
More quotes
1 week
2 079.95
Extreme 2079.95
2 286.95
1 month
2 051.60
Extreme 2051.6
2 311.95
Current year
1 998.35
Extreme 1998.35
2 353.95
1 year
1 246.75
Extreme 1246.75
2 353.95
3 years
1 061.77
Extreme 1061.7667
2 353.95
5 years
550.00
Extreme 550
2 353.95
10 years
259.52
Extreme 259.52
2 353.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 98-12-31
Chief Executive Officer 52 95-12-31
Director of Finance/CFO 59 98-04-22
Members of the board TitleAgeSince
Chief Executive Officer 52 95-12-31
Chairman 77 79-12-30
Director/Board Member 78 08-10-19
More insiders
Date Price Change Volume
24-04-26 2,194 +2.50% 205,252
24-04-25 2,140 +0.29% 35,470
24-04-24 2,134 +0.16% 69,788
24-04-23 2,130 +1.86% 98,235
24-04-22 2,091 +0.29% 138,405

Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am

More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,194 INR
Average target price
2,271 INR
Spread / Average Target
+3.54%
Consensus
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock